Compare Procter & Gamble Health with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs SUN PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH SUN PHARMA PROCTER & GAMBLE HEALTH/
SUN PHARMA
 
P/E (TTM) x 51.9 28.4 183.1% View Chart
P/BV x 4.7 2.4 191.8% View Chart
Dividend Yield % 10.1 0.7 1,546.7%  

Financials

 PROCTER & GAMBLE HEALTH   SUN PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
SUN PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,549679 522.8%   
Low Rs1,301375 346.6%   
Sales per share (Unadj.) Rs511.4121.1 422.2%  
Earnings per share (Unadj.) Rs61.313.4 458.2%  
Cash flow per share (Unadj.) Rs74.020.7 357.8%  
Dividends per share (Unadj.) Rs440.002.75 16,000.0%  
Dividend yield (eoy) %18.10.5 3,477.6%  
Book value per share (Unadj.) Rs927.8172.6 537.6%  
Shares outstanding (eoy) m16.602,399.26 0.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.4 109.0%   
Avg P/E ratio x39.639.4 100.4%  
P/CF ratio (eoy) x32.825.5 128.6%  
Price / Book Value ratio x2.63.1 85.6%  
Dividend payout %717.920.6 3,492.0%   
Avg Mkt Cap Rs m40,2571,264,650 3.2%   
No. of employees `0001.117.5 6.5%   
Total wages/salary Rs m1,31359,671 2.2%   
Avg. sales/employee Rs Th7,486.716,608.1 45.1%   
Avg. wages/employee Rs Th1,157.63,409.6 34.0%   
Avg. net profit/employee Rs Th897.21,833.8 48.9%   
INCOME DATA
Net Sales Rs m8,490290,659 2.9%  
Other income Rs m24410,255 2.4%   
Total revenues Rs m8,734300,914 2.9%   
Gross profit Rs m1,48263,076 2.3%  
Depreciation Rs m21117,533 1.2%   
Interest Rs m05,553 0.0%   
Profit before tax Rs m1,51450,246 3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m66-12,144 -0.5%   
Tax Rs m5636,009 9.4%   
Profit after tax Rs m1,01732,093 3.2%  
Gross profit margin %17.521.7 80.4%  
Effective tax rate %37.112.0 310.6%   
Net profit margin %12.011.0 108.5%  
BALANCE SHEET DATA
Current assets Rs m15,343310,692 4.9%   
Current liabilities Rs m1,960173,396 1.1%   
Net working cap to sales %157.647.2 333.7%  
Current ratio x7.81.8 436.8%  
Inventory Days Days4999 49.2%  
Debtors Days Days28112 25.5%  
Net fixed assets Rs m1,209232,477 0.5%   
Share capital Rs m1662,399 6.9%   
"Free" reserves Rs m15,235411,691 3.7%   
Net worth Rs m15,401414,091 3.7%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m17,595646,938 2.7%  
Interest coverage xNM10.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.4 107.4%   
Return on assets %5.85.8 99.4%  
Return on equity %6.67.8 85.2%  
Return on capital %10.310.2 100.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63666,025 2.5%   
Fx outflow Rs m4,36838,610 11.3%   
Net fx Rs m-2,73227,415 -10.0%   
CASH FLOW
From Operations Rs m-1,30421,965 -5.9%  
From Investments Rs m12,697-6,813 -186.4%  
From Financial Activity Rs m-301-27,305 1.1%  
Net Cashflow Rs m11,093-8,442 -131.4%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 5.1 354.8%  
FIIs % 1.0 23.0 4.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 8.3 350.6%  
Shareholders   28,591 133,026 21.5%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  UNICHEM LAB  WYETH LTD  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 17, 2019 01:39 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS